期刊文献+

自动化系统在水痘疫苗半成品配制中的应用

Application of automatic system in preparation of semi-finished varicella vaccine products
原文传递
导出
摘要 目的应用自动化系统进行水痘疫苗的半成品配制,以降低劳动强度,提高产品均一性。方法采用自动化系统完成水痘疫苗的原液稀释和半成品分装,并与人工操作方法进行比较,比较两种方法的清洁、灭菌和保温效果以及疫苗半成品、成品的检定结果。结果自动化操作可使工作人员减少60%,工时缩短80%。两种方法对容器或罐体的清洗和灭菌效果均达到工艺要求。采用自动化方法保温时温度可控。用自动化操作系统制备的半成品疫苗,其滴度差异小于人工操作方法,变异系数分别为0.00)%和2.17%。两种方法生产的成品疫苗的稳定性试验结果均达到标准[病毒滴度不低于3.3lg蚀斑形成单位(plaque-formingunit,PFU)/o.5ml]。自动化和人工方法生产的成品疫苗于37℃放置7d,病毒滴度分别为3.7和3.6lgPFU/0.5ml;于2~8℃放置18个月分别为3.5和3.4lgPFU/0.5ml。结论将自动化系统应用于水痘疫苗的原液稀释、半成品分装,可降低劳动强度,提高产品的均一性。 Objective To reduce labor intensity and increase homogeneity of varicella vaccine by application of automatic system for preparation of semi finished products. Methods The dilution of varicelia vaccine bulk and filling of semi-finished product were conducted by either the automatic system or a manual method. The cleaning, sterilizing and insulating effects of containers and verification results of semi-finished and final products were compared between the two methods. Results Automatic operation reduced 60% labor and 80% work time. The cleaning and sterilizing effects of container or tank by both methods complied with process requirements. The temperature maintenance was well controlled by the automatic method. Difference among the virus titers of semi-finished products produced by automatic system was much smaller as compared with manual method, with coefficient of variation at 0. 00% and 2. 17%, respectively. The stability test results of final products met the titer requirement -- no less than 3.3 lg plaque-forming unit (PFU)/0. 5 ml. The virus titers of final products produced by automatic and manual methods were 3. 7 and 3. 6 lgPFU/(1. 5 ml at 37℃ for 7 d, and 3. 5 and 3. 4 lgPFU/0. 5 ml at 2-8℃ for 18 months. Conclusion The use of automatic system for bulk dilution and semi-filling can reduce labor intensity and improve homogeneity of the product.
出处 《国际生物制品学杂志》 CAS 2017年第2期58-61,共4页 International Journal of Biologicals
关键词 水痘疫苗 自动化 工艺学 制药 药物稳定性 Ch^ckenpox vaccine Automation Technology, pharmaceutical Drug stability
  • 相关文献

参考文献6

二级参考文献35

  • 1寇桂英,包红,傅生芳,王名强,余黎,周旭.细胞工厂在轮状病毒基因重配株LD9培养中的应用初探[J].微生物学免疫学进展,2011,39(3):10-14. 被引量:4
  • 2庞成华,彭佩霞,刘小琳,王桂秋,陈秀珍,王用楫.北京株水痘活疫苗的研制[J].中国生物制品学杂志,1994,7(4):156-158. 被引量:6
  • 3赵慧,段鸿元,李晓萸,赵卓,康晓平,秦鄂德.细胞密度和感染复数对SARS病毒在Vero细胞中增殖的影响[J].生物技术通讯,2005,16(3):274-275. 被引量:10
  • 4国家食品药品监督管理局,药品安全监管司,药品认证管理中心.药品生产质量管理规范实施指南[M].北京:化学工业出版社,2003.
  • 5国家食品药品监督管理局,药品安全监管司,药品认证管理中心.药品生产验证指南--设备的清洁验证[M].北京:化学工业出版社,2003.
  • 6TAKAHASHI M. Current status and prospects of live varicella vaccine[J]. Vaccine, 1992, 10(14): 1007-1014.
  • 7ARVIN AM. Varicella-zoster virus [ J ]. Clin Microbiol Rev, 1996, 9(3): 361 -381.
  • 8SHEFFER R, SEGAL D, RAHAMANI S, et al. Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel[J]. Pediatr Infect Dis J,2005, 24(5): 434 -437.
  • 9HAMBLETON S, GERSI-ION AA. Preventing varicella-zoster disease[J]. Clin Microbiol Rev, 2005, 18 ( 1 ) : 70 - 80.
  • 10WHO. TRS requirement for varicella vaccine (live) [ S]. 1994: 222 - 381.

共引文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部